The Netherlands offers pharmaceutical firms a favorable environment for receiving expedited study review. Clinical studies can be rapidly initiated in The Netherlands due to Dutch government regulations for clinical research. Based on years of experience operating in the Netherlands, this whitepaper will: - Outline the regulatory guidelines for studies in The Netherlands. - Highlight advantages for sponsors conducting studies in The Netherlands. - Provide details on how to appropriately navigate regulatory procedures in The Netherlands.